Chromium 3’ Single Cell Solution used in First-of-its-kind Clinical Trial
The discovery of new strategies to personalize treatment for pediatric patients is a major initiative, and has seen an influx of funding with the promise to accelerate translation into the clinic. Now researchers at Seattle Children’s Hospital have announced the first clinical trial applying next-generation T-cell receptor (TCR) sequencing and single-cell gene expression analysis to better understand how the immune system drives both inflammatory bowel disease (IBD) in pediatric autoimmunity patients and graft-versus host disease (GVHD) in pediatric bone marrow transplant (BMT) patients.
This first-of-its-kind clinical trial, dubbed PREDICT - for Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation, is expected to first provide clinicians new information about why IBD arises in children, allowing them to tailor treatment plans to each patient. The trial, led by principal investigator Dr. Leslie Kean, will use 10x Genomics Chromium™ Single Cell 3’ Solution to discover gene expression patterns in each participant’s individual T cells. Combined with next-generation TCR sequencing, researchers hope to gain a clearer understanding of the molecular signatures of T cells in IBD and GVHD and identify new therapeutic targets and better treatment approaches.
Read more on genomeweb: Seattle Children's Trial Aims to ID Immune Pathways in IBD, Graft Versus Host Disease
- PREDICT Study
- See the Press Release on the Seattle Children’s website
- Read more about Dr. Leslie Kean
- Learn more about the Chromium Single Cell 3’ Solution